Comparison of efficacy and toxicity according to etoposide and cytarabine dosing in BEAM conditioning followed by autologous stem cell transplantation in Hodgkin lymphoma

References

• Armitage JO, Bierman PJ, Vose JM, et al. Autologous bone marrow transplantation for patients with relapsed Hodgkin’s disease. Am J Med. 1991;91(6):605–611. doi:10.1016/0002-9343(91)90213-h
   PubMed Web of Science ®Google Scholar
• Chopra R, McMillan A, Linch D, et al. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin’s disease. A single-center eight- year study of 155 patients. Blood. 1993;81(5):1137–1145. doi:10.1182/blood.V81.5.1137.1137
   PubMed Web of Science ®Google Scholar
• Kessinger A, Bierman PJ, Vose JM, et al. High-dose cyclophosphamide, carmustine, and etoposide followed by autologous peripheral stem cell transplantation for patients with relapsed Hodgkin’s disease. Blood. 1991;77(11):2322–2325.
   PubMed Web of Science ®Google Scholar
• Linch DC, Winfield D, Goldstone AH, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin’s disease: results of a BNLI randomised trial. Lancet. 1993;341(8852):1051–1054. doi:10.1016/0140-6736(93)92411-l
   PubMed Web of Science ®Google Scholar
• Reece DE, Barnett MJ, Connors JM, et al. Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin’s disease. J Clin Oncol. 1991;9(10):1871–1879. doi:10.1200/JCO.1991.9.10.1871
   PubMed Web of Science ®Google Scholar
• Brice P, Bouabdallah R, Moreau P, et al. Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin’s disease: analysis of 280 patients from the french registry. Société française de greffe de moëlle. Bone Marrow Transplant. 1997;20(1):21–26. doi:10.1038/sj.bmt.1700838
   PubMed Web of Science ®Google Scholar
• Majhail NS, Weisdorf DJ, Defor TE, et al. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin’s lymphoma. Biol Blood Marrow Transplant. 2006;12(10):1065–1072. doi:10.1016/j.bbmt.2006.06.006
   PubMed Web of Science ®Google Scholar
• Sirohi B, Cunningham D, Powles R, et al. Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin’s lymphoma. Ann Oncol. 2008;19(7):1312–1319. doi:10.1093/annonc/mdn052
   PubMed Web of Science ®Google Scholar
• Sureda A, Constans M, Iriondo A, et al. Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin’s lymphoma autografted after a first relapse. Ann Oncol. 2005;16(4):625–633. doi:10.1093/annonc/mdi119
   PubMed Web of Science ®Google Scholar
• Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet. 2002;359(9323):2065–2071. doi:10.1016/S0140-6736(02)08938-9
   PubMed Web of Science ®Google Scholar
• Gaspard MH, Maraninchi D, Stoppa AM, et al. Intensive chemotherapy with high doses of BCNU, etoposide, cytosine arabinoside, and melphalan (BEAM) followed by autologous bone marrow transplantation: toxicity and antitumor activity in 26 patients with poor-risk malignancies. Cancer Chemother Pharmacol. 1988;22(3):256–262. doi:10.1007/BF00273421
   PubMed Web of Science ®Google Scholar
• Caballero MD, Rubio V, Rifon J, et al. BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors. Bone Marrow Transplant. 1997;20(6):451–458. doi:10.1038/sj.bmt.1700913
   PubMed Web of Science ®Google Scholar
• Mills W, Strang J, Goldstone AH, et al. Dose intensification of etoposide in the BEAM ABMT protocol for malignant lymphoma. Leuk Lymphoma. 1995;17(3–4):263–270. doi:10.3109/10428199509056831
   PubMed Web of Science ®Google Scholar
• Di Francia R, Crisci S, De Monaco A, et al. Response and toxicity to cytarabine therapy in leukemia and lymphoma: from dose puzzle to pharmacogenomic biomarkers. Cancers (Basel). 2021;13(5):966. doi:10.3390/cancers13050966
   PubMed Web of Science ®Google Scholar
• Martín A, Caballero MD, Pérez-Simón JA, et al. Results of autologous transplantation in lymphoma are not improved by increasing the dose of etoposide in the BEAM regimen: a single-centre sequential-cohort study. Bone Marrow Transplant. 2004;34(8):675–682. doi:10.1038/sj.bmt.1704595
   PubMed Web of Science ®Google Scholar
• Milpied N, Deconinck E, Gaillard F, et al. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med. 2004;350(13):1287–1295. doi:10.1056/NEJMoa031770
   PubMed Web of Science ®Google Scholar
• Martin N, Borchiellini D, Coso D, et al. High-dose chemotherapy with carmustine, etoposide, cytarabine and melphalan followed by autologous stem cell transplant is an effective treatment for elderly patients with poor-prognosis lymphoma. Leuk Lymphoma. 2015;56(8):2379–2387. doi:10.3109/10428194.2014.1001987
   PubMed Web of Science ®Google Scholar
• Duong HK, Savani BN, Copelan E, et al. Peripheral blood progenitor cell mobilization for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American society for blood and marrow transplantation. Biol Blood Marrow Transplant. 2014;20(9):1262–1273. doi:10.1016/j.bbmt.2014.05.003
   PubMed Web of Science ®Google Scholar
• Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin’s disease. International prognostic factors project on advanced Hodgkin’s disease. N Engl J Med. 1998;339(21):1506–1514. doi:10.1056/NEJM199811193392104
   PubMed Web of Science ®Google Scholar
• Eghbali H, Raemaekers J, Carde P. The EORTC strategy in the treatment of Hodgkin’s lymphoma. Eur J Haematol Suppl. 2005;75(66):135–140. doi:10.1111/j.1600-0609.2005.00467.x
   Google Scholar
• Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315(8):801–810. doi:10.1001/jama.2016.0287
   PubMed Web of Science ®Google Scholar
• Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579–586. doi:10.1200/JCO.2006.09.2403
   PubMed Web of Science ®Google Scholar
• Gribben JG, Linch DC, Singer CR, et al. Successful treatment of refractory Hodgkin’s disease by high-dose combination chemotherapy and autologous bone marrow transplantation. Blood. 1989;73(1):340–344.
   PubMed Web of Science ®Google Scholar
• Phillips GL, Bernstein SH, Liesveld JL, et al. A phase I trial: dose escalation of melphalan in the ‘BEAM’ regimen using amifostine cytoprotection. Biol Blood Marrow Transplant. 2011;17(7):1033–1042. doi:10.1016/j.bbmt.2010.11.003
   PubMed Web of Science ®Google Scholar
• Khattry N, Gupta A, Jain R, et al. LACE versus BEAM conditioning in relapsed and refractory lymphoma transplant: retrospective multicenter analysis of toxicity and efficacy. Int J Hematol. 2016;103(3):292–298. doi:10.1007/s12185-015-1927-5
   PubMed Web of Science ®Google Scholar
• Sakellari I, Mallouri D, Batsis I, et al. Carmustine, etoposide, cytarabine and melphalan versus a newly designed intravenous busulfan-based busulfex, etoposide and melphalan conditioning regimen for autologous hematopoietic cell transplant: a retrospective matched-pair analysis in advanced Hodgkin and non-Hodgkin lymphomas. Leuk Lymphoma. 2015;56(11):3071–3081. doi:10.3109/10428194.2015.1028054
   PubMed Web of Science ®Google Scholar
• Argiris A, Seropian S, Cooper DL. High-dose BEAM chemotherapy with autologous peripheral blood progenitor-cell transplantation for unselected patients with primary refractory or relapsed Hodgkin’s disease. Ann Oncol. 2000;11(6):665–672. doi:10.1023/a:1008396525292
   PubMed Web of Science ®Google Scholar